Articles tagged with Neuroprotection
Researchers at Salk Institute discover sterubin, a potent neuroprotective compound in Yerba santa, which may help counteract aging's effects on the brain. The study suggests that sterubin could be a promising treatment for Alzheimer's disease.
Researchers at Lehigh University identify fruit fly protein Scarlet as a key to preventing age-dependent loss of dopaminergic neurons in Parkinson's disease. The study found that Scarlet has a neuroprotective role in a model of the disease, suggesting potential for future treatments.
Researchers from Brigham and Women's Hospital discovered a neuroprotective microRNA, miR-132, which shows promise in treating tauopathies like Alzheimer's. The study found that miR-132 supplementation reduced toxic forms of tau and glutamate excitotoxicity, providing new avenues for potential treatments.
Mesencephalic astrocyte-derived neurotrophic factor MANF administered to rats after ischemic brain injury promoted reversal of behavioral impairments. MANF treatment transiently increased phagocytic macrophages, suggesting a potential beneficial effect on inflammation and tissue repair.
Researchers at MUSC find that adding vitamin D to hypothermia and N-acetylcysteine treatment improves sensorimotor function, working memory, and reduces brain injury volume in male newborns. Vitamin D deficiency is prevalent in both males and females, highlighting the need for sex-based treatment approaches.
Researchers have found an epilepsy drug that can protect nerve damage in MS patients, according to a study published in the Lancet Neurology. The anti-convulsant drug phenytoin protected neural tissue in patients with optic neuritis, a symptom of MS.
Researchers at Penn Medicine have discovered hypermethylation of the C9orf72 gene may protect against certain neurodegenerative diseases. Patients with hypermethylation showed more dense grey matter in affected brain regions, suggesting a potential neuroprotective target for drug discovery.
The study investigates DJ-1's role in the oxidative stress cell death cascade after stroke, revealing its importance as an anti-oxidative stress therapeutic target. DJ-1 translocation to mitochondria may mitigate mitochondrial injury and promote neuroprotection.
Researchers successfully constructed an adenovirus that induces DHCR24 specifically in neuronal cells, demonstrating its neuroprotective effects against amyloid beta-induced apoptosis. This breakthrough paves the way for further studies on DHCR24 gene therapy and neuronal functional research.
Researchers used PET imaging to study Tongxinluo's neuroprotective effects in rats. The study found that Tongxinluo reduced brain damage after middle cerebral artery occlusion, highlighting its potential as a treatment for acute stroke.
Researchers found that Asiaticoside pretreatment decreased neuronal cell loss and restored apoptotic-related protein expressions. It also inhibited Ca2+ influx induced by N-methyl-D-aspartate receptors, providing new insights into its neuroprotective effects.
Researchers found that ischemic preconditioning reduced infarct volume and increased vascular endothelial growth factor (VEGF) immunoreactivity in rats. The study suggests a potential neuroprotective effect of ischemic preconditioning in focal cerebral infarction, associated with VEGF upregulation.
Researchers found that L-carnitine administration improved axon area, myelin sheath area, and numerical density of myelinated axons, suggesting neuroprotective effects on sciatic nerve crush injury in rats. These findings indicate potential benefits of L-carnitine for treating nerve damage.
Researchers found that Neuropeptide Y prevents excessive production of cytokines, reduces microglial reactivity, and inhibits N-methyl-D-aspartate current in rat cortical neurons. This study suggests a potential neuroprotective role for Neuropeptide Y in cerebral cortical neurons.
The study found that low concentrations of lithium carbonate had a protective effect on SH-SY5Y cells, with reduced expression levels of pyruvate kinase 2 and calmodulin 3. Additionally, western blot analysis revealed increased expression of stress proteins GRP94 and HSP27.
Researchers found that apolipoprotein E-derived therapeutic peptide improves synaptic stability and learning memory performance after diffuse brain injury. Apolipoprotein E mimetic peptide also reduces neuronal apoptosis by suppressing the ERK1/2-Bax mitochondrial apoptotic pathway.
Researchers successfully constructed an adenovirus that induces DHCR24 specifically in neuronal cells, leading to reduced apoptosis. The findings suggest potential for future studies on DHCR24 gene therapy and neuronal functional research.
A $16 million phase III study of isradipine as a potential neuroprotective agent in Parkinson's disease will be conducted at 56 sites in North America. Researchers aim to delay disease progression by protecting dopamine-producing neurons from toxicity.
Researchers developed a reliable 3-D MRI imaging technique to study premature brain development. This allows for early identification of delayed tracts and potential treatments, enabling proactive therapies within weeks of birth.
Research found that 60-minute sevoflurane preconditioning reduces infarct volume and apoptotic cells, but longer durations do not provide additional benefits. The study suggests that shorter preconditioning periods may be more effective in protecting against cerebral ischemia.
Researchers at the University of Oxford have identified a natural biological mechanism that allows brain cells to survive during a stroke, enabling the development of potential neuroprotective drugs. The 'endogenous neuroprotection' discovered in rats has shown to increase cell survival by stimulating production of hamartin protein.
Researchers at AxoGlia Therapeutics and the Luxembourg Centre for Systems Biomedicine have received a grant to identify new neuroprotective therapeutic targets for Parkinson's disease. The project aims to disrupt the CD40/CD40-Ligand neuroinflammatory pathway, which could lead to new avenues for therapeutic interventions.
A team of scientists at Scripps Research Institute has been awarded $2.1 million to study compounds that may improve the quality of life for ALS patients by inhibiting the JNK enzyme. The study aims to develop a neuroprotective drug to prevent motor neuron death and lengthen patients' lifespan.
A new study suggests that NA-1, a neuroprotective agent, may reduce brain lesions and damage after stroke surgery. The research found significantly fewer lesions in patients who received the drug compared to those who received a saline control, although there was no difference in volume of lesions recorded.
A study published in Restorative Neurology and Neuroscience found that a therapy combining exercise with the neurovascular protective agent GSNO improved recovery from stroke in a rat model. Exercise alone did not significantly reduce infarct volume, but combined with GSNO, it provided greater functional improvement.
Researchers found that mesenchymal stem cell transplantation in animal models of amyotrophic lateral sclerosis (ALS) and spinal cord injury promotes functional recovery. Bone marrow cell transplantation coupled with granulocyte colony-stimulating factor also shows neuroprotective and angiogenic effects in ALS animal models.
Researchers at University of South Florida found that spirulina supplementation delayed motor symptoms and disease progression in a mouse model of ALS. The study suggests a dual antioxidant and anti-inflammatory effect on motor neurons, offering potential clinical benefits for ALS patients.
Researchers at the Salk Institute found that fisetin slows the onset of motor problems and delays death in three models of Huntington's disease. The study suggests that fisetin may be able to slow down the progression of the disease in humans, improving quality of life for those affected.
Researchers found a compound called P7C3 that improves newborn neuron survival and reduces programmed cell death in the brain's memory hub. This discovery offers new hope for treating Alzheimer's disease by targeting the underlying neuroprotective mechanism.
Researchers have developed a non-invasive brain scanning technique that may help diagnose Parkinson's disease and track its progression. The technique uses diffusion tensor imaging to examine the substantia nigra region of the brain, which produces dopamine.
A new study found a low number of strokes and cardiac events in patients treated with the FiberNet Embolic Protection System during carotid stenting. The system's unique filter design and ease of use contributed to these low event rates.
A study published in PLoS ONE suggests that a mere 5% increase in cognitive reserve can prevent one-third of Alzheimer's cases. The research supports the notion that public health policies focused on education are likely the best strategy for preventing Alzheimer's disease.
Researchers have discovered a new compound that specifically targets FKBP38 receptor, reducing programmed cell death in neuronal cells. The compound protects neurons and promotes neural stem cell proliferation, offering potential therapeutic application for stroke and other neurodegenerative diseases.
Neural transplants have provided long-term clinical benefits to three patients with Huntington's disease, improving motor and cognitive function. The procedure also led to focal improvements in brain metabolic activity, while secondary clinical alterations were observed due to the ongoing disease process.
A new study explores the potential of erythropoietin (EPO) as a neuroprotective agent for schizophrenia. EPO was found to penetrate the blood-brain barrier and enhance cognitive functioning in patients with schizophrenia. The results suggest that EPO may be a promising compound for preventing loss of brain function in this disease.
A recent mouse study identified a compound, NAPVSIPQ, that protects embryos from alcohol-induced toxicity by blocking the effects of ethanol on the L1 cell adhesion molecule. This finding suggests a new target for medication development to prevent fetal alcohol damage.
Researchers at Virginia Tech are developing a 'prodrug' to deliver neuroprotective compounds to the brain, overcoming limited solubility issues. The approach aims to inhibit monoamine oxidases and neuronal nitric oxide synthase enzymes involved in Parkinson's disease.
Researchers found that pramipexole prevented nearly 100% of brain cells from dying in mice with a Parkinson's-like condition. The drug also showed neurotrophic effects by increasing dopamine cell size, suggesting potential as a neuroprotective agent.